Search Results

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.

• Authors : Srichumpuang C; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.; Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Subjects: Factor VIII* ; Hemophilia A*/Hemophilia A*/Hemophilia A*/drug therapy; Humans

• Source: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Mar 26; Vol. 19 (1), pp. 135. Date of Electronic Publication: 2024 Mar 26.Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172

Record details

Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report.

• Authors : Berger C; Hematology and Oncology Pediatric Unit, Haemophilia CRC Hospital of Saint-Etienne, Saint-Etienne, France.; INSERM, Lyon University, Jean Monnet University, Sainbiose, France.

Subjects: Factor VIII*/Factor VIII*/Factor VIII*/therapeutic use ; von Willebrand Disease, Type 3*/von Willebrand Disease, Type 3*/von Willebrand Disease, Type 3*/complications ; von Willebrand Disease, Type 3*/von Willebrand Disease, Type 3*/von Willebrand Disease, Type 3*/drug therapy

• Source: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2186332.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454

Record details

An intronic RNA element modulates Factor VIII exon-16 splicing.

• Authors : Tse V; Department of Molecular, Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, CA, 95064, USA.; Center for Molecular Biology of RNA, University of California Santa Cruz, Santa Cruz, CA, 95064, USA.

Subjects: Factor VIII*/Factor VIII*/Factor VIII*/genetics ; Introns* ; RNA Splicing*

• Source: Nucleic acids research [Nucleic Acids Res] 2024 Jan 11; Vol. 52 (1), pp. 300-315.Publisher: Oxford University Press Country of Publication: England NLM ID: 0411011 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Special Issue "Development and Synthesis of Biologically Active Compounds".

• Authors : Gazieva, Galina A.¹ (AUTHOR) ; Chegaev, Konstantin² (AUTHOR)

• Source: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p4015. 5p.

Record details

Association between fatty liver index and blood coagulation markers: a population-based study.

• Authors : Iglesias Morcillo M; Epidemiology, University of Augsburg, University Hospital Augsburg, Stenglinstr. 2, Augsburg, 86156, Germany.; Freuer D

Subjects: Factor VIII* ; Hemostatics*; Male

• Source: Lipids in health and disease [Lipids Health Dis] 2023 Jun 29; Vol. 22 (1), pp. 83. Date of Electronic Publication: 2023 Jun 29.Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X

Record details

Development and Validation of an HPLC-UV Method for the Quantification of Acyclovir and Ganciclovir in the Plasma of Pediatric Immunocompromised Patients.

• Authors : Franzin, Martina¹ (AUTHOR) ; Ruoso, Rachele¹ (AUTHOR); Del Savio, Rossella¹ (AUTHOR)

Subjects: *IMMUNOCOMPROMISED patients; *GANCICLOVIR; *ACYCLOVIR

• Source: International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 5, p2685. 12p.

Record details

Combined life‐threatening internal organ bleeding and postpartum hemorrhage associated with acquired hemophilia A.

• Authors : Kanitthamniyom, Chanakarn¹ (AUTHOR); Siladech, Pharit² (AUTHOR); Polpichai, Natchaya³ (AUTHOR)

• Source: Clinical Case Reports. Jan2024, Vol. 12 Issue 1, p1-4. 4p.

Record details

Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.

• Authors : Kragh N; Global Health Economics and Outcomes Research, Swedish Orphan Biovitrum AB (Sobi™), Stockholm, Sweden.; Tytula A

Subjects: Factor VIII*/Factor VIII*/Factor VIII*/therapeutic use ; Hemophilia A*/Hemophilia A*/Hemophilia A*/therapy; Humans

• Source: European journal of haematology [Eur J Haematol] 2023 Mar; Vol. 110 (3), pp. 262-270. Date of Electronic Publication: 2022 Dec 11.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

Record details

Liposomal factor VIII as an efficient pharmaceutical system for the treatment of hemophilia.

• Authors : Karimi, Maryam^1,2; Rezayat, Seyed Mahdi³; Mortazavi, Seyed Alireza¹

• Source: Iranian Journal of Basic Medical Sciences. Jun2024, Vol. 27 Issue 6, p747-754. 8p.

Record details

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A.

• Authors : Xiao R; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.; Chen Y

Subjects: Hemophilia A*/Hemophilia A*/Hemophilia A*/genetics ; Hemophilia A*/Hemophilia A*/Hemophilia A*/therapy ; Hemostatics*

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 24; Vol. 25 (7). Date of Electronic Publication: 2024 Mar 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details